logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
C

Carolina Urologic Research Center

Scholars170
Papers237
Citations286
Related Papers (235)
Publication Date
delete
Correspondence: persistence, progression, and PSA: what exactly does DEAR-EXT compare? Yanping Zhu, Xiaohui Wang, Yang Zhang, Shuangwu Lv
errProstate Cancer and Prostatic Diseases
IF5.8
err2026-08-18
err0
errOAAI
errNeal D. Shore; Daniel J. George; Nasreen Khan; Niculae Constantinovici; Guifang Chen; Mercedeh Ghadessi; Vlasta Hlebec; Alicia K. Morgans
errShare
errSave
Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial
errEuropean Urology
IF25.2
err2026-08-13
err0
PREAI
errFred Saad; Neal Shore; Egils Vjaters; David Olmos; Natasha Littleton; Isabella Testa; Mindy Mo; Frank Verholen; Shankar Srinivasan; Kunhi P. Haresh
errShare
errSave
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
errLancet Oncology
IF35.9
err2026-07-27
err0
PREAI
errMark D Tyson; Jong-Kil Nam; Shreyas S Joshi; Edward M Uchio; Seung Il Jung; Trinity J Bivalacqua; Gary D Steinberg; Neal D Shore; James M Burke; Hiroshi Kitamura; Ben Tran; Roger Li
errShare
errSave
Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019
errEuropean Urology
IF25.2
err2026-07-11
err0
PREAI
errNeal D. Shore; Stephen J. Freedland
errShare
errSave
Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice
errFuture Oncology
IF2.6
err2026-07-09
err0
errOAAI
errStephen J. Freedland; Neal D. Shore
errShare
errSave
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
errInternational Journal of Clinical Oncology
IF2.8
err2026-06-25
err0
errOAAI
errNeal Shore; Nguyen; Barinder Kang; Amrita Sawhney; Clare Byrne; Jackson Tang; Magdaliz Gorritz; Chi-Chang Chen; Jeetvan Patel
errShare
errSave
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non–muscle-invasive Bladder Cancer
errEuropean Urology Open Science
IF4.5
err2026-06-13
err0
errOAAI
errJennifer Linehan; Piyush K. Agarwal; Xianne Penny; Max Kates; Joseph Jacob; Seth P. Lerner; Rhonda C. Kines; John T. Schiller; Elisabet de los Pinos; Neal D. Shore; Jill Hopkins; Joseph McQuaid; Sabine D. Brookman-May
errShare
errSave
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer
errFuture Oncology
IF2.6
err2026-06-09
err0
errOAAI
errNeeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
errShare
errSave
Sasanlimab taken together with Bacillus Calmette–Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary
errFuture Oncology
IF2.6
err2026-05-24
err0
errOAAI
errNeal D. Shore; Thomas B. Powles; Jens Bedke; Matthew D. Galsky; Joan Palou Redorta; Ja Hyeon Ku; Michal Kretkowski; Evanguelos Xylinas; Boris Alekseev; Dingwei Ye; Félix Guerrero-Ramos; Alberto Briganti; Girish S. Kulkarni; Julia Brinkmann; Anna-Maria Calella; Rossano Cesari; Anthony Eccleston; Elisabete Michelon; Jennifer Vermette; Caimiao Wei; Gary D. Steinberg
errShare
errSave
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer
errTherapeutic Advances in Medical Oncology
IF4.2
err2026-05-21
err0
PREAI
errMehmet A. Bilen; Benjamin H. Lowentritt; Sabree Burbage; Charmi Patel; Carmine Rossi; Frederic Kinkead; Gordon Wong; Dominic Pilon; Neal D. Shore
errShare
errSave
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
errFuture Oncology
IF2.6
err2026-05-10
err0
PREAI
errNeal D. Shore; Karim Fizazi; Michael Thomas Schweizer; Elena Castro; Arun A. Azad; Daniel J. George; Karine Martins da Trindade; Hao Zeng; Nitin Shrivastava; Svitlana Tonkovyd; Amy Bock; Srilakshmi Nekkalapudi; Yiyun Tang; Stella Lin; Neeraj Agarwal
errShare
errSave
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
errEuropean Urology Oncology
IF9.3
err2026-05-02
err0
PREAI
errMarinela Augustin; Brigitte Laguerre; Capucine Baldini; Ahmed H. Zedan; Enrique Gonzalez-Billalabeitia; Peter C. Fong; Ruslan Zukov; Peter Hammerer; Mark Prentice; Neal Shore; Andrea Necchi; Tilman Todenhöfer; Elizabeth R. Kessler; Fatih Kose; Howard Gurney; Begona P. Valderrama; Pengfei Zhu; Kentaro Imai; Yingjie Liu; Ray McDermott
errShare
errSave
Reply to Editorial Comment on "Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer"
errUrology
IF2
err2026-05-01
err0
PREAI
errShore, Neal
errShare
errSave
Consensus Recommendations for Disease-and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel
errJournal of the National Comprehensive Cancer Network
IF16.4
err2026-05-01
err0
PREAI
errFreedland, Stephen J.; Aronson, William; Asher, Arash; Lemke, Emily; Golant, Mitch; Morgans, Alicia K.; Morris, David; Sullivan, Carol; Sutton, Jennifer; Thomson, Cynthia A.; Twardowski, Przemyslaw; Wefel, Jeffrey S.; Winters-Stone, Kerri; Chakoian, Marty; Wells, Ted; ElSouda, Dina; Turnbull, James; Buzaglo, Joanne; Mobley, Claire; Ivanova, Jasmina; Cohen, Jason; Hogue, Susan; El-Chaar, Nader; Touya, Maelys
errShare
errSave
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer
errJournal of Comparative Effectiveness Research
IF2.5
err2026-01-01
err0
PREAI
errShore, Neal; Morgans, Alicia K.; Paracha, Noman; Thom, Howard; Keeney, Edna; Orishaba, Philip; Phillippo, David; Aceituno, David; Wallis, Christopher J. D.; Gallagher, Elaine; Boegemann, Martin
errShare
errSave
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
errCANCER MEDICINE
IF3.1
err2025-12-26
err0
errOAAI
errSaar, Matthias; Fizazi, Karim; Shore, Neal D.; Smith, Matthew; Damber, Jan-erik; Semenov, Andrey; Ribal, Maria J.; Birtle, Alison; Rigaud, Jerome; Wallis, Christopher J. D.; Grimm, Marc-oliver; Halabi, Susan; Armstrong, Andrew J.; Mohamed, Ateesha F.; Adorjan, Patrick; Srinivasan, Shankar; Verholen, Frank; Morgans, Alicia K.; Siemens, D. Robert
errShare
errSave
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
errNature Communications
IF15.7
err2025-12-17
err0
errOAAI
errSoumyajit Roy; Yilun Sun; Maha Hussain; Kim N. Chi; Karim Fizazi; Ian D. Davis; Susan Halabi; Neeraj Agarwal; Simon Chowdhury; Bertrand Tombal; Scott C. Morgan; Shawn Malone; Pedro C. Barata; Michael Ong; Christopher J. D. Wallis; Alejandro Berlin; Umang Swami; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Jorge A. Garcia; Prateek Mendiratta; Jason R. Brown; Vinod V. Subhash; Martin R. Stockler; Hayley Thomas; Rana R. McKay; Eric J. Small; Neal D. Shore; Fred Saad; Christopher J. Sweeney; Daniel E. Spratt
errShare
errSave
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data
errProstate Cancer and Prostatic Diseases
IF5.8
err2025-12-09
err0
errOAAI
errNeal Shore; Alicia K. Morgans; Noman Paracha; Elaine Gallagher; Howard Thom; David Aceituno; Philip Orishaba; Stephen Stefani; Quoc-Dien Trinh; Christopher J. D. Wallis; Keith R. Abrams; Martin Boegemann
errShare
errSave
Response to Letter to the Editor Regarding: ‘Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'
errAdvances in Therapy
IF4
err2025-11-28
err0
errOAAI
errMehmet A. Bilen; Benjamin Lowentritt; Ibrahim Khilfeh; Carmine Rossi; Shawn Du; Frederic Kinkead; Lilian Diaz; Dominic Pilon; Lorie Ellis; Neal D. Shore
errShare
errSave
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]
errEuropean Journal of Cancer
IF7.1
err2025-11-13
err0
PREAI
errArun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
errShare
errSave